| Therapeutic | Eculizumab |
| Target | C5 |
| Heavy Chain | QVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS |
| Light Chain | DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK |
| 100% seqID Fv Structure | 5i5k%3AHL%3AXY [Fvs: ] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 5i5k%3AHL%3AXY [Fvs: ] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G2 |
| Highest Clinical Trial (August '23) | Approved |
| Estimated Status (August '23) | Active |
| Recorded Developmental Technology | GS Gene Expression System |
| INN Year Proposed | 2002 |
| INN Year Recommended | 2003 |
| Companies Involved | Alexion Pharmaceuticals%3BBrigham and Womens Hospital%3BChiba University%3BHandok Inc |
| Conditions Approved | Haemolytic uraemic syndrome%3BMyasthenia gravis%3BParoxysmal nocturnal haemoglobinuria |
| Conditions Active | Neuromyelitis optica%3BDelayed graft function%3BGuillain-Barre syndrome%3BRenal transplant rejection |
| Conditions Discontinued | Antiphospholipid syndrome%3BHeart transplant rejection%3BAdult respiratory distress syndrome%3BAge-related macular degeneration%3BAllergic asthma%3BAutoimmune haemolytic anaemia%3BBullous pemphigoid%3BDermatomyositis%3BGlomerulonephritis%3BIdiopathic thrombocytopenic purpura%3BLupus nephritis%3BMembranous glomerulonephritis%3BMotor neuron disease%3BPsoriasis%3BRheumatoid arthritis%3BSystemic lupus erythematosus |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
